Sign In
21 Oct 2011 07:00
For immediate release 21 October 2011
ABCAM PLC
("Abcam" or "the Company")
AGM Statement
Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, is this morning holding its Annual General Meeting. Michael Redmond, Abcam's Chairman, will make the following statement at the meeting:
"Last month, at the time of the announcement of our preliminary results, we highlighted the uncertainty surrounding the levels of centrally funded research expenditure amongst Western economies. This uncertainty remains a feature of our markets and it is unlikely to change in the near future. However, in spite of this backdrop, our product portfolio and revenues continue to grow and we remain on track to meet the Board's profit expectations.
"Separately, we announced today the appointment of two new Non-Executive Directors, Murray Hennessy and Michael Ross, who will join the Board on 1 November 2011. Both Murray and Michael have outstanding e-commerce experience and I am delighted to welcome them to the Abcam Board. I look forward to their valuable input to the next stage of Abcam's growth."
For further information please contact:
Abcam | + 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer Jeff Iliffe, Chief Financial Officer www.abcam.com | |
| |
Numis Securities | + 44 (0) 20 7260 1000 |
Michael Meade / Nick Westlake - Nominated Adviser James Black - Corporate Broking | |
| |
Buchanan Communications | + 44 (0) 20 7466 5000 |
Mark Court / Jessica Fontaine |
Notes for editors
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA. (USA), Eugene, OR. (USA), Tokyo (Japan) and Hong Kong (China) allowing it to serve a global customer base in over 85 countries. Abcam employs over 340 staff across its six operating companies.
Abcam now has an online catalogue of over 79,000 products sourced from more than 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed e-commerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research tools globally.
Follow the stocks
